However, the combined treatment of everolimus with SFN inhibits drug resistance and significantly decreases cell proliferation via the downregulation of proteins such as p-Akt, p27, p-CDK1, CDK2, cyclin A, and cyclin B, therefore suggesting SFN to be a potential chemosensitizer against drug resistant bladder cancer [71]. The gene discussed is AKT1; the disease is urinary bladder carcinoma.